The Latest Breaking News from Ginkgo Bioworks

COVID Genetic Material Turned Up in 98% of Air Samples at Newark, Dulles, Dallas, and San Francisco Airports

CDC-led air sampling at four U.S. airports detected COVID genetic material in 98% of samples. What that does and doesn't mean for travel risk.

Medical Daily · Sep 21

I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

Barchart · Sep 3, 2025

Why the CDC is inviting travelers from China to swab their noses at LAX

LAX's arrivals area in the Tom Bradley International Terminal is now filling with the sounds of Mandarin, Cantonese, Hunanese and other languages as travelers from China seize the chance to enter the United States for the first time in nearly three years.

Los Angeles Times · Jan 4, 2023

Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock

Ark Investment Management, led by Tesla Inc.

Benzinga · May 19, 2022

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

Benzinga · May 18, 2022

Why Ginkgo Bioworks Stock Is Falling After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company 

Benzinga · May 16, 2022

Is Ginkgo Bioworks a Buy Under $5?

Cell programming platform operator Ginkgo Bioworks (DNA) went public late last year in an SPAC merger. Since then, the stock has plummeted more than 60% in price, closing yesterday’s session at $4.13. In addition, analysts have increased their loss per share expectations for the stock for this year. So, would…

StockNews.com · Apr 5, 2022

Here's Why Ginkgo Bioworks Shares Are Rising

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.

Benzinga · Mar 29, 2022

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported 

Benzinga · Mar 29, 2022

Why Ginkgo Bioworks Stock Is Rising After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates. 

Benzinga · Mar 28, 2022